Adenoviral vectors infect cells through the binding of capsid proteins to cell-surface receptors. The ubiquitous expression of adenoviral receptors in human tissues represents an obstacle toward the development of systemically deliverable vectors for cancer therapy, since effective therapy may require delivery to specific sites. For these reasons, major efforts are directed toward the elimination of the native tropism combined with identification of ligands that bind to tumor-specific cell-surface proteins. Highthroughput technologies have identified potential targeting ligands, which need to be evaluated for their ability to retarget adenovirus to alternative receptors. Here, we present a strategy that permits the routine analysis of adenoviral targeting ligands.
Introduction
Adenoviral vectors are efficient gene delivery vehicles that readily transduce dividing and quiescent cells. Adenovirus (Ad) infects a broad range of cells via the interaction of the capsid fiber protein with the cell surface, coxsackie-Ad receptor (CAR). Cellular infection by an adenoviral particle involves at least two distinct virus-cell interactions involving first the interaction of the fiber with CAR 1 then an interaction between penton base RGD sequences and the avb3 and avb5 cell surface integrins. 2 The integrins act as coreceptors and potentiate viral internalization into an endosomal pathway. Notwithstanding the high efficiency of Ad infection, a major drawback of the technology results from the widespread tissue distribution of CAR and preferential Ad accumulation in the liver when the virus is administered systemically. This has fueled efforts to develop methods to redirect Ad to tissue-specific receptors. To date, attention has focused on strategies that disrupt the interaction of the fiber with CAR with simultaneous insertion of ligands capable to redirect Ad to targeted sites. 3, 4 This is accomplished by mutating critical residues involved in the interaction with CAR and inserting ligands into the fiber protein, [4] [5] [6] [7] [8] [9] or by using a moiety that binds specifically to the fiber to which the ligands are attached. [10] [11] [12] [13] Both strategies suffer from the speed at which adenoviral targeting ligands can be assessed, because of the efforts required to clone and produce functional adenoviral vectors, and the technical difficulties related to the preparation of bifunctional conjugates. Here, we present a strategy that permits the routine analysis of adenoviral targeting ligands. We use intein-mediated protein ligation as a means of preparing bifunctional conjugates, that is, Ad targeting molecules that function as adapters between cellular receptors and the Ad fiber protein.
Inteins are catalytic domains involved in protein splicing. Protein splicing involves the self-catalyzed excision of an intervening sequence, the intein, from a precursor protein, with the concomitant ligation of the flanking extein sequences to yield a new polypeptide. 14 The discovery of inteins as protein-splicing domains has led to the development of a ligation technique, inteinmediated protein ligation (IPL) , that allows for the versatile attachment of molecules to native proteins. 15 IPL takes advantage of the catalytic activity of the intein to generate an activated thioester bond at the C-terminus of the protein of interest, to which virtually any molecular probes can be ligated. Examples include the incorporation of noncoded amino acids into a protein sequence, 16 synthesis of cytotoxic proteins, 17 segmental labeling of proteins for NMR analysis, 18 the addition of fluorescent probes to create biosensors 19 and the synthesis of glycoproteins. 20 Here, we show that IPL can be utilized to attach an array of targeting ligands that differ in size and nature to an Ad binding moiety, that is, peptides, proteins and small molecules. Our objective in the present work was to develop a convenient method to generate functional biological molecules that mediate Ad targeting to tumor cells.
Results

Production of D1 targeting molecules
Several nongenetic approaches using adenoviral targeting molecules have been developed to target adenoviral vectors both in vitro and in vivo. Ad targeting molecules are bifunctional conjugates containing a moiety that binds to an adenoviral capsid protein and a ligand that binds specifically to a cellular receptor. [10] [11] [12] [13] Previous studies have shown that fusion of peptide targeting ligands to the extracellular domain of CAR produces chimeric proteins that can be used to retarget adenoviral vectors to alternative receptors. 12, 21, 22 Here, the immunoglobulin D1 domain of CAR was selected to be the Adbinding moiety instead of the entire extracellular domain previously used.
12 CAR D1 is a 14 kDa protein that binds to the adenoviral fiber knob domain with moderate affinity in solution (K d ¼20-25 nM) 23 and can be expressed in Escherichia coli.
CAR D1
25 was fused to the GyrA intein protein splicing element 26 and a chitin-binding domain to produce D1-GyrA. This fusion protein was overexpressed in E. coli and immobilized on a chitin column (Figure 1a ). Insertion of a 24 amino-acid spacer between CAR D1 and the intein was necessary to recover D1-GyrA in the soluble fraction of the cell lysates (data not shown) and also appeared to eliminate the variability of the autosplicing reaction known to depend on intein proximal sequences. 27 After immobilization of D1-GyrA on the chitin resin, we used an excess of 2-mercaptoethanesulfonic acid (MESNA) to generate an activated thioester bond on the C-terminus of CAR D1 ( Figure  1a) . Targeting ligands bearing an amino-terminal cysteine residue can be ligated to activated CAR D1 by native chemical ligation, 28 a reaction that results in the formation of a covalent amide bond at the ligation site. The ligation reaction of folate to CAR-D1 is diagrammed in Figure 1a to generate the D1-folate targeting molecule shown schematically in Figure 1b . This system was also utilized to conjugate an apolipoprotein E (apoE) synthetic peptide and the basic fibroblast growth factor (FGF2) protein. These ligands are known to redirect adenoviral-mediated gene delivery, when conjugated to an antifiber knob monoclonal antibody 10, 11 or to the extracellular domain of CAR. 12 Thus, the CAR D1 conjugates D1-apoE, D1-FGF2, D1-folate should in principle be capable of redirecting Ad binding to their respective receptors. After ligation and purification, the molecular weight and homogeneity of each D1-targeting molecule were analyzed by electrospray mass spectroscopy. In each case, a single peak of the expected molecular weight was obtained.
Retargeting Ad through lipoprotein-related receptors
To demonstrate that a peptidic ligand can be utilized in the present system, we attached to CAR D1 a 38-aminoacid targeting peptide containing a tandemly repeated 15mer sequence derived from apoE. 29 This apoE peptide is a synthetic mimic of plasma apoE that binds the lowdensity lipoprotein-related receptor (LRP). 29 This peptide is known to retarget Ad-mediated gene delivery, when fused to the extracellular domain of CAR. 12 To evaluate the ability of D1-apoE to alter adenoviral tropism, we transduced HDF cells, a human diploid fibroblast cell line expressing high levels of LRP receptors but not CAR 12, 30 with Av3GFP, a nonreplicating vector expressing green fluorescent protein (GFP). 31 Av3GFP was mixed with increasing amounts of D1-apoE and added to the cells (Figure 2a ). The percent transduction was dependent upon the amount of D1-apoE added and ranged from 15 up to 100% positive cells. To confirm that . 17 The cleavage reaction releases CAR D1 with a C-terminal activated thioester while GyrA-CBD remains bound on the chitin column. (b) Structural representation of the Ad targeting molecule D1-folate. Targeting ligands (TL) are attached to the CAR D1 moiety (ribbon structure) bearing a spacer at its C-terminus to generate D1-folate, D1-FGF2 and D1-apoE.
Synthesis of adenoviral targeting molecules by IPL O Nyanguile et al transduction of these cells occurred via binding to LRP, competition analysis was carried out. As shown in Figure  2b , the targeting effect of D1-apoE could be significantly reduced in the presence of an anti-LRP monoclonal antibody or the synthetic apoE peptide, molecules that compete with binding at the LRP receptor. These results demonstrate that ligation of peptides to D1 via IPL produces functional molecules that can retarget Ad to alternative receptors.
Retargeting Ad through FGF receptors
Ligand insertion into the fiber of Ad and successful retargeting have been demonstrated with peptidic ligands varying from 9 to 30 residues 5-9 and more recently with peptides as large as 100 amino acids. 32 Although the insertion of ligands such as scFv is conceivable, incorporation of large ligands may affect the folding of the fiber. For these reasons, retargeted gene delivery with larger ligands has only been successful using bifunctional conjugates. 11, 21 To demonstrate the feasibility of attaching proteins to CAR D1, we evaluated if basic FGF2 could be utilized as a ligand. FGF2 is a 17 kDa protein that binds to FGF receptors (FGFRs) with picomolar affinity. 33 As with FRs, FGFRs are of interest for gene therapy because of their presence at the surface of several human cancers including ovarian and Kaposi's sarcoma. 11, 13 Inspection of the crystal structure of FGF2 bound to the FGFR1 receptor 34 revealed that the Nterminus of FGF2 is exposed at the surface of the dimeric complex. We inferred that attachment of D1 to the Nterminus of FGF2 would not interfere with receptor interaction. As described in the Materials and Methods, the N-terminal cysteine residue necessary for the ligation step was engineered by expressing FGF2 as Ssp-FGF2 fusion protein. The Synechocystis sp. dnaB gene (Ssp) 35 consists of a mini-intein that allows for the generation of proteins with a N-terminal cysteine. Av3GFP was mixed with increasing amounts of D1-FGF2 and the bound complex was used to infect SKOV-3 ovarian carcinoma cells (Figure 3a) . Previous studies have shown that SKOV-3 cells are refractory to adenoviral infection probably because of the absence of CAR. 21 In addition, both high-and low-affinity FGFRs are available on this cell line for FGF2 binding. 13 As shown in Figure 3a , the percentage of transduction was dependent upon the amount of D1-FGF2 added and ranged from 10 up to 100% positive cells. The specificity of the FGF2 ligand was verified through competition analysis (Figure 3b ). The targeting effect of D1-FGF2 was significantly reduced in the presence of an anti-FGF2 polyclonal antibody or recombinant FGF2, reagents that prevent access to the FGF receptors. Addition of excess trimeric fiber knob (1.6 mM) competed with the binding of Ad to D1-FGF2, thereby preventing the formation of the Ad/ 
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Retargeting Ad through folate receptors
Folic acid has been previously used for retargeted adenoviral gene delivery. 10 Folic acid binds to folate receptors (FRs) with high affinity (K d B1 nM). FRs are overexpressed on a number of human cancers, particularly ovarian carcinomas and brain tumors. 36 To prepare folic acid for ligation using IPL, folic acid was derivatized with an ethylenediamino linker at a position that does not interfere with receptor interaction 31 ( Figure 1a ), to which was attached a cysteine residue necessary for the ligation step. Av3GFP was mixed with increasing amounts of D1-folate and the bound complex was added to KB cells, a human nasopharyngeal carcinoma cell line expressing high levels of folate receptors 31 ( Figure 4a ). The percent transduction was dependent upon the amount of D1-folate added and ranged from 26 up to 55% positive cells. To confirm that transduction of these cells occurred via binding to FRs, competition analysis was carried out (Figure 4b ). The targeting effect of D1-folate could be reduced in the presence of added folic acid, a molecule that competes with binding of the Av3GFP/D1-folate complex to FRs. Inhibition of Ad transduction was also observed when the cells were transduced with Av3GFP complexed to D1, confirming that the effect observed with D1-folate was mediated by the ligand. These results demonstrate that small molecules can be successfully ligated to D1 by IPL and used as reagents to retarget Ad to alternative receptors.
Effect of binding affinity on retargeted gene delivery
Last, we investigated the correlation between the affinity of the Ad binding moiety for the fiber and of the targeting ligand for its cellular receptor on the efficiency of retargeted gene delivery. The amount of bifunctional conjugate required for optimal adenoviral-mediated gene delivery should be dependent on the affinity of both moieties. To assess this point, we compared the amount of each D1-targeting molecule that was needed for maximum transduction relative to the affinity of D1 interacting with fiber knob or each ligand with its receptor (Table 1) . We compared D1-FGF2 to FGF-Fab, a bifunctional conjugate known to retarget Ad to FGFRs through binding of the same targeting ligand FGF2, 11 in SKOV3 cells. As shown in Table 1 , we found that 14 nM of D1-FGF2 was required to achieve maximal GFP expression as opposed to only 0.24 nM FGF-Fab as previously reported. 37 These results indicate that the use of a higher affinity Ad-binding moiety such as the antifiber Fab achieves a stronger association with the adenoviral capsid that results in the use of lower concentrations of the Ad targeting molecule.
Next, we evaluated the effect of ligand affinity. For each Ad targeting molecule, the affinity of the fiber knob interaction with D1 presumably was the same, approximately 20 nM. 23 We found that the amount of D1-conjugate needed for maximal GFP expression appeared to be related to the ligand's affinity for its receptor. For example, only 14 nM of the D1-FGF2 molecule was needed to achieve the maximum number of GFP-positive cells compared with 280 nM for D1-apoE. Conditions were probably not optimal for D1-folate, because of the nonselective derivatization of folic acid at its a and g carboxylate position that results in the presence of a nonactive form (D1-a-folate) in an approximate ratio of 70:30 of g carboxyl:a carboxyl-derivatized protein. 38 These data suggest that ligand affinity may also have an effect on the in vitro targeting efficiency of bifunctional conjugates. Competition assay. KB cells were transduced with 100 ppc Av3GFP premixed with 718 nM D1-folate or 25 mg D1 as described in the Materials and methods. Competition experiments was carried out in the presence 50 mg folic acid, prior to addition to the cells. CAR D1 was prepared as described for D1-apoE except 5 mM cysteine was used during the ligation step. IPL allows for the fusion of two disparate molecules and has been used in a variety of settings. There are several advantages of using CAR D1 IPL to generate adenoviral targeting molecules. First, the ligation reaction is a relatively simple procedure that can be applied to a variety of ligands. Once the ligand has been modified to include a N-terminal cysteine, it is then mixed with the activated D1 protein, which results in the formation of a native peptide bond. Second, large quantities of the D1 protein can be expressed in E. coli for subsequent use in the ligation reaction. This greatly simplifies the procedure since the same preparation of the activated D1 molecule can be used to prepare a variety of bifunctional conjugates in a short time frame, approximately 1 week. Except for small molecules, incorporation of a cysteine residue is straightforward. Custom-made peptides are readily available and the sequence can be easily modified to include an additional amino acid. Larger proteins can be cloned in-frame to the C-terminus of a mini-intein using a commercial cloning vector. As described here for FGF2, protein ligands can be expressed as fusion proteins in E. coli and immobilized on a chitin resin, a simple pH and temperature shift then releases the target protein with a N-terminal cysteine. 35 The use of synthetic ligands will require derivatization for incorporation of the cysteine residue necessary for the ligation step. Once modified, in addition to single compounds like folate, libraries of various small molecules can be evaluated for use in adenoviral targeting. A limitation of CAR D1 IPL consists in the orientation of ligands on D1, which may prevent effective receptor interaction. Previous studies have shown that improper orientation can result in nonfunctional molecules, as has been shown for gastric releasing peptide. 39 We note that CAR D1 IPL will not be appropriate for ligands that need to be located at the Nterminus of the bifunctional molecule.
The success of Ad targeting depends on the identification of ligands that bind to receptors specifically overexpressed at the surface of target cells. Considerable efforts are directed toward in vitro 40 and in vivo 41 phagedisplay biopanning with the aim to identify peptides that bind specifically to tumor cells. A subsequent step of this approach is to assess whether peptides isolated by phage-display can retarget Ad to tumor cells. CAR D1 IPL provides a means to determine if peptides identified by phage display do alter adenoviral tropism. A lung-homing peptide has been successfully conjugated to an antifiber Fab and shown to redirect Ad to the appropriate target cell, 42 thereby suggesting that bifunctional conjugates can be utilized for such a screening effort.
The present demonstration that IPL can be used to prepare Ad targeting molecules that are functional in vitro, suggests that it should be feasible to use D1 targeting molecules in vivo. Although at this stage, the prospect of using D1 conjugates for Ad systemic administration requires further refinements. Our data indicate that the efficiency of the D1 targeting molecules correlates with the affinity of the Ad binding moiety for the fiber protein. This implies that affinity of the Ad binding moiety for the fiber or any other suitable Ad capsid protein, such as hexon, must be sufficient to prevent dissociation of the bound complex in the blood stream. To date, systemic delivery of Ad has been achieved using FGF-Fab or Fab-9B9, bifunctional conjugates that retarget Ad to FGFRs 43 or to the angiotensin-converting enzyme (ACE), 44 respectively. The Fab fragment used in these studies binds with high affinity to the fiber knob (K d ¼0.31 nM). This suggests that a tight interaction between bifunctional conjugates and Ad capsid proteins is required for successful in vivo application. In spite of these exciting perspectives, systemic administration is still hampered by significant residual liver transduction, 43, 44 which may be because of partial dissociation of the bound complex. It is unlikely that the interaction between D1 and the fiber knob is sufficient to prevent dissociation. Despite this limitation, the system described here provides an effective means for screening ligands in vitro.
Materials and methods
Production and purification of D1
A DNA fragment encoding the D1 domain of CAR (D1: amino-acid residues 15-140) was generated by PCR as a NdeI-SacI DNA fragment and cloned into the pTWIN-MBP1 vector (New England Biolabs, Beverly MA, USA). This cloning strategy generated a pTWIN-D1 expression construct encoding the D1-GyrA-CBD fusion protein, which contains a 24-amino-acid spacer between CAR D1 and the Mxe GyrA mini-intein. pTWIN-D1 was transformed into the E. coli Bl21(DE3) strain, cells were grown at 371C in 1 l of LB broth (100 mg/ml ampicillin) to an optical density of 0.4 at 600 nm, after which the culture was induced with 0.3 mM isopropyl-b-D-thiogalactopyranoside (IPTG) and transferred to 181C. Cells were harvested after overnight incubation, lysed by sonication in Buffer E (20 mM Tris-HCl (pH 7.5), 100 mM NaCl), and centrifuged at 30,000 Â g for 30 min. The supernatant was loaded on a column packed with chitin resin (5 ml bed volume) equilibrated in Buffer E. Unbound proteins were washed from the column with 80 ml of Buffer E. Intein-mediated generation of the CAR D1 C-terminal thioester was initiated by quickly flushing the column with 15 ml of a 100 mM solution of MESNA-(Aldrich, Milwaukee WI, USA) in Buffer E, after which the flow was stopped and the cleavage reaction was allowed to proceed overnight at 41C. CAR D1 was eluted with 7 ml of 100 mM MESNA in Buffer E and concentrated on a Centriprep 3 centrifugal filter device. The protein concentration was determined using the Coomassie plus protein assay (Pierce, Rockford, IL, USA) using BSA as a protein standard. Expression and purification of FGF2. A cDNA fragment encoding basic FGF2 (GenBank Accession No. NM 002006) was generated by PCR as a SapI-PstI fragment and cloned into the pTWIN2 vector (New England Biolabs, Beverly, MA, USA). Additional nucleotides, encoding the sequence Asn-Cys-Arg required for expressed protein ligation, 27 were included after the SapI site as recommended by the manufacturer (New England Biolabs, IMPACTt-TWIN). The SapI site present in the FGF2 cDNA was eliminated prior to PCR by sitedirected mutagenesis using a mutation that maintained identical codon translation (QuickChanget site directed mutagenesis kit, Stratagene, La Jolla, CA, USA). The primer sequence was 5 0 -CGGGGTCCGGGAGAAAAGC GACCCTCACATC-3 0 . This cloning strategy generated a pTWIN2-FGF2 expression construct encoding the CBDSsp-FGF2 fusion protein. Protein expression was performed as described for D1-GyrA in 2 l of LB broth. Cells were lysed in Buffer C (20 mM Tris-HCl (pH 8.5), 500 mM NaCl, 1 mm EDTA) and the cleared cell lysate was loaded onto 7.5 ml (bed volume) of a chitin resin column. After washing with 120 ml Buffer C, intein-mediated generation of the FGF2 protein was initiated with a rapid flush-through of 22.5 ml Buffer D (20 mM Tris-HCl (pH 7.0), 500 mM NaCl, 1 mM EDTA). After 48 h incubation at room temperature, FGF2 was eluted with 14 ml Buffer D and concentrated on a Centriprep 3.
Derivatization of folic acid. In preparation for ligation to CAR D1, folate was derivatized in three steps. First, a cysteine residue necessary for the ligation step to D1 was attached to an ethylenediamino linker to generate N-atrityl-S-trityl-L-cysteine-ethylenediamine. This reagent was made as follows: ethylenediamine (97.35 ml, 110 mmol) was added to a solution of Trt-Cys(Trt)-OSu (860 mg, 1.1 mmol, Novabiochem, San Diego, CA, USA) in 23 ml of dichloromethane. After stirring for 5 h at room temperature, the reaction mixture was diluted with dichloromethane (35 ml), after which the organic phase was washed extensively with water and dried over Na 2 SO 4 . Evaporation yielded 649 mg of a yellowish amorphous powder. The molecular weight of the product was characterized by fast-atom bombardment high-mass resolution spectroscopy: HRMS (FAB) for C 43 Production of D1 targeting molecules D1-apoE. The apoE peptide (200 ml, 2 mM) was slowly added (50 ml aliquot) to CAR D1 (300 ml, 0.24 mM) and 2 ml of 1 M NaOH. After a 18 h incubation at 41C, the pH of the solution was adjusted to 9-9.5 by addition of 8 ml of 1 M NaOH. After a 48 h incubation at 41C, the ligation reaction went essentially to completion as determined by SDS-PAGE. The product was purified by size-exclusion chromatography on a Superdex 75 HR 10/30 column (Amersham Pharmacia Biotech, Piscataway, NJ, USA 0.5 ml/min) using 10 mM Pipes pH 6.0, 100 mM NaCl as the elution buffer. The ligation mixture was injected into the column (500 ml injection loop) and collected fractions were analyzed by SDS-PAGE. Fractions containing D1-apoE were combined and characterized by electrospray high-mass resolution spectroscopy. HRMS (ESI-MS) for C 923 H 1500 N 264 O 299 S 6 , 22 994.3, calcd 21 272.0 (M).
D1-FGF2.
The thioester tagged D1 prepared as described above in Buffer A (20 mM Tris-HCl (pH 8), 500 mM NaCl, 1 mM EDTA) was ligated to FGF2 by protein-protein ligation. 45 CAR D1 (1 ml, 0.122 mM in Buffer A) was combined with FGF2 (1 ml, 0.127 mM in Buffer D) in a Centricon 3 centrifugal filter device and the ligation mixture was concentrated to a final volume of 460 ml (0.27 mM each protein). After a 48 h incubation at 41C, the product was purified by size-exclusion chromatography as described above using 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 1 mM EDTA as the elution buffer and a 200 ml injection loop. D1-folate. L-cysteine-ethylenediamine-a,g-folate (1.8 mg, 2.21 mmol) was resuspended in 100 ml Buffer E and dissolved with 6.6 ml of 1 M NaOH. CAR D1 (366 ml, Synthesis of adenoviral targeting molecules by IPL O Nyanguile et al 0.59 mM) was combined with L-cysteine-ethylenediamine-a,g-folate (80 ml, 20.7 mM) and the pH of the solution was adjusted to 8.5-9.0 by addition of 6 ml of 1 M NaOH. After a 48 h incubation at 41C, the product was purified by size-exclusion chromatography as described above using Buffer E as the elution buffer. Fractions containing D1-folate that were estimated to be 490% homogenous as determined by SDS-PAGE were combined and incubated for 60 min with 750 ml of chitin beads to remove the cleaved intein that had eluted during the D1-GyrA cleavage step. Approximately 330 mg of homogenous D1-folate was isolated using this procedure. HRMS (ESI-MS) for C 757 H 1194 N 208 O 243 S 6 , 17 430.3 (M+MESNA), calcd 17 289.59 (M). The observed mass corresponded to disulfide formation of D1-folate with MESNA at the ligation site. DTT can be used after the ligation step in order to reduce any unwanted disulfide bonds, 20 but was not used here to avoid reduction of the CAR D1 endogenous disulfide bond. was used in these studies to evaluate the function of each adenoviral targeting molecule. Av3GFP, a third generation vector in which the E1, E2a and E3 regions were deleted, 46 contains the GFP cDNA under the control of the RSV promoter. Viral particle titers (particles per ml) were determined as described previously. 47 Adenoviral transduction and competition. Cells were seeded into six-well plates at a density that achieved approximately 80% confluency after an overnight incubation. Av3GFP was incubated for 30 min at room temperature with the CAR D1 targeting molecules in 100 ml of serum-free media. Following incubation, the complexes were diluted to 500 ml with culture medium containing 2% FBS and added to the cell monolayers that had been washed with PBS. Cell transduction proceeded for 1 h at 371C in a 5% CO 2 incubator, after which the cells were washed with PBS and further incubated 24-36 h in 3 ml of culture media. Cells were harvested with Trypsin-Versene (Life Technologies, Inc.), detached with a cell-lifter and pelleted by centrifugation in 5 ml polystyrene tubes (12 Â 75 mm 2 , Falcon 2052). After fixing the cells in 300 ml-2 ml PBS containing 1% paraformaldehyde, adenoviral-mediated GFP expression was analyzed by flow cytometry. Data are presented as the percentage of fluorescent-positive cells (corrected for background controls). The data are the averages of duplicate determinations. Each experiment was repeated a minimum of three times.
Adenoviral transduction assay
To demonstrate the specificity of complex formation or receptor interaction, the virus complexes were incubated with the appropriate competitor. For disruption of the viral complex, excess free recombinant Ad5 fiber knob protein was added. The DNA fragment encoding the Ad5 fiber knob domain was cloned into pET15b 24 and recombinant Ad5 fiber knob was purified as described previously. 48 The competitor used to assess the interaction of the synthetic ligand, folate with its receptor was excess free folic acid. The competitors used to assess the interaction of the apoE peptide with its receptor were a mouse monoclonal antibody against the human LDL receptor-related protein (LRP) (Research Diagnostics, Inc., Flanders, NJ, USA) or the free apoE peptide. The competitors used for the FGF2 constructs included recombinant FGF2 or a rabbit anti-FGF2 polyclonal antibody (Sigma Chemical Co., St Louis, MO, USA).
